Allarity Therapeutics Files 8-K Amendment
Ticker: ALLR · Form: 8-K/A · Filed: May 24, 2024 · CIK: 1860657
Sentiment: neutral
Topics: amendment, filing-update
TL;DR
Allarity filed an amendment to its 8-K, updating previous disclosures. Check for details.
AI Summary
Allarity Therapeutics, Inc. filed an amendment (8-K/A) on May 24, 2024, to its Form 8-K originally filed on May 14, 2024. This amendment pertains to the results of operations and financial condition, other events, and financial statements and exhibits. The filing does not provide new specific financial figures or operational details beyond indicating an amendment to previously reported information.
Why It Matters
This filing indicates a correction or addition to previously disclosed information, which could be important for investors to understand the company's current financial status and operational events.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, not a new event, and does not introduce new material financial information.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- May 14, 2024 (date) — Date of earliest event reported
- May 24, 2024 (date) — Filing Date
- 001-41160 (other) — SEC File Number
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previously filed Form 8-K, intended to update or correct information related to the results of operations and financial condition, other events, and financial statements and exhibits.
When was the original 8-K filed?
The original Form 8-K was filed on May 14, 2024.
What specific new financial information is provided in this amendment?
The filing does not appear to introduce specific new dollar amounts or detailed financial figures; it serves as an amendment to previously reported information.
What is the principal executive office address for Allarity Therapeutics, Inc.?
The principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108.
What is the SEC file number for Allarity Therapeutics, Inc.?
The SEC file number for Allarity Therapeutics, Inc. is 001-41160.
Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-05-24 08:55:19
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea0206741-8ka1_allarity.htm (8-K/A) — 26KB
- 0001213900-24-046439.txt ( ) — 200KB
- allr-20240514.xsd (EX-101.SCH) — 3KB
- allr-20240514_lab.xml (EX-101.LAB) — 33KB
- allr-20240514_pre.xml (EX-101.PRE) — 22KB
- ea0206741-8ka1_allarity_htm.xml (XML) — 4KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On May 14, 2024, the Company issued a press release announcing its financial results for its fiscal quarter ended March 31, 2024 (the "Press Release"). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01 Other Events
Item 8.01 Other Events. The Press Release discussed that the Company concluded its Phase 2 clinical trial of stenoparib early due to clear clinical benefits observed, including tumor shrinkage and long-term disease stability, in heavily pre-treated ovarian cancer patients. Using the Company's DRP companion diagnostic to pre-screen patients, the trial targeted those most likely to benefit. The promising results have provided sufficient proof of concept, prompting the Company to halt enrollment with the purpose of preparing a follow-on trial with FDA regulatory intent.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated May 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer Dated: May 24, 2024 3